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　Recently, new treatment guidelines and classifications were proposed for the management of 
pancreatic neuroendocrine tumors（P-NETs）, and are now being used in clinical practice. The 
World Health Organization classification published in 2010 emphasized the importance of a grading 
system for P-NETs based on parameters of proliferative activity, such as mitotic count and Ki-67 
labeling index, proposed by the European Neuroendocrine Tumor Society. For surgical treatment 
of P-NETs, it is important to select a strategy based on the degree of tumor malignancy. However, 
there are still no clear indications for organ-preserving pancreatic resection or lymph node dissection. 
This article outlines the surgical management and clinicopathological features of P-NETs. There 
are various surgical options, such as tumor enucleation, spleen-preserving distal pancreatectomy
（SpDP），distal pancreatectomy with splenectomy, pancreatoduodenectomy, and duodenum-
preserving pancreatic head resection. Hepatectomy is the first choice for liver metastasis from well-
differentiated neuroendocrine carcinoma without extrahepatic metastasis. Other treatment options 
are radiofrequency ablation, transarterial chemoembolization/ embolization, and liver transplantation. 
Systematic chemotherapy, biotherapy such as somatostatin analogue and interferon-α, and targeted 
therapy are used for recurrence after surgery and unresectable tumors. This article also gives details 
of the surgical techniques available for tumor enucleation and SpDP.
Key words: pancreatic neuroendocrine tumor, enucleation, spleen-preserving distal pancreatectomy, 
Liver metastasis
Introduction
Pancreatic neuroendocrine tumors（P-NETs）are 
comparatively rare neoplasms, and account for only 
1%–2% of all pancreatic neoplasms. The incidence of 
P-NETs is approximately 1 per 100 000 people１）－５）. 
The incidence in autopsy cases ranges from 0.26% to 
1.4%６），７）. An autopsy study of 800 elderly subjects 
obtained specimens cut every 5 mm and found tiny 
neuroendocrine tumors（NETs）in more than 10% 
of the cases８）.
P-NETs include benign neoplasms without 
metastasis or invasion, as well as high-grade 
malignant neoplasms. The assessment of tumor 
malignancy is important for determining the surgical 
strategy for P-NETs. In 2000 and 2004, the World 
Health Organization（WHO）classified P-NETs 
into three categories – well-differentiated NETs
（benign or uncertain behavior），well-differentiated 
neuroendocrine carcinoma（NEC）, and poorly 
differentiated NEC – according to the presence 
or absence of metastasis, direct invasion, arterial 
or venous invasion, perineural invasion, hormonal 
syndrome, tumor size, histological differentiation, and 
Ki-67 index９），10）.
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The European Neuroendocrine Tumor Society
（ENETS）proposed guidelines for the treatment and 
prognostic stratification of gastroenteropancreatic 
NETs in 2006 by histological differentiation according 
to the WHO classification, the TNM classification, 
and grading based on proliferative activity, such as 
Ki-67 labeling index and mitotic count11），12）（Table 1）.
The American Joint Committee on Cancer（AJCC）
proposed a new TNM classification for P-NETs 
in 200913）. This classification is used for pancreatic 
ductal adenocarcinoma; the AJCC applied the same 
classification for P-NETs. 
In the WHO classification published in 201014），
the grading system proposed by the ENETS11），
12）was considered important. Well-differentiated 
NETs were classified into NET G1 and NET G2, 
and poorly differentiated carcinoma was classified 
into  NEC14）（Table  2）.  The 2000/2004 WHO 
histological classification included TNM elements 
such as tumor size and metastasis９），10）, but in the 
2010 WHO classification14），the TNM classification
（AJCC-TNM）was adopted for these factors. There 
are two major differences between the AJCC-TNM 
classification and the ENETS-TNM classification: 
the definition of the T stages and the consideration 
of tumor grading based on proliferative activity. 
Both TNM classifications are effective prognostic 
indicators15）－19）. However, they are not free of 
problems20），21）. The fact that there are two TNM 
classifications actually causes confusion among many 
practitioners.
P -NET G3 was newly added to the wel l -
differentiated pancreatic neuroendocrine neoplasm 
category of the WHO classification published in 
201722）（Table 3）. Grade 3（ki-67 > 20%）tumors 
include biologically distinct subtypes. For example, 
Sorbye et al. reported that Grade 3 tumors with Ki-
67 < 55% had a lower response rate to platinum-
based chemotherapy（15% vs. 42%, P < 0.001）, but 
better survival than Grade 3 tumors with Ki-67 ≥ 
55%（14 months vs. 10 months, P<0.001）23）. Raj et al. 
reported that the response rate to platinum-based 
chemotherapy was 10% in Grade 3 well-differentiated 
P-NETs and 37% in poorly differentiated pancreatic 
NEC and that overall survival was significantly 
longer in Grade 3 well-differentiated P-NETs 
compared with G3 pancreat ic NEC24）.  Wel l -
differentiated P-NETs are more likely to have loss 
of nuclear expression of DAXX or ATRX, and 
preserved expression of Rb and p5325），26）. Therefore, 
well-differentiated P-NET G3 is an entity that should 
be distinguished from poorly differentiated NEC. 
In the 2017 WHO classification, the same TX-T3 
factors used in the ENETS-TNM classification were 
applied for the T-factor in the TNM classification 
of well-differentiated pancreatic neuroendocrine 
neoplasms22）（Table 4）. Distant metastases were 
subclassified as M1a for liver metastasis alone, 
M1b for extrahepatic metastasis alone, and M1c 
for concurrent liver metastasis and extrahepatic 
metastasis. Stage subclassifications were eliminated 
and replaced with a simple system divided into 
stages I, II, III, and IV. The TNM classification for 
pancreatic ductal adenocarcinoma was applied for 
pancreatic NEC22）.
This article describes surgical strategies and 
options for the treatment of P-NETs.
 
 
 
 
 
 
 
 
 
Table 1．A grading system for neuroendocrine tumors proposed by the 
European Neuroendocrine Tumor Society [11, 12]. 
Grade                Mitotic count (10 HPF)a        Ki-67 index (%)b 
G1                         <2                          ≦2 
G2                         2-20                        3-20 
G3                         >20                         >20 
a Ten HPF : High power field = 2 mm2 , at least 40 fields, evaluated in areas at 
highest mitotic density  
b MIB 1 antibody: Percent of 2,000 cells in areas of highest nuclear labeling  
Table１．A grading system for neuroendocrine tumors 
proposed by the European Neuroendocrine Tumor 
Society [11, 12].
Tab l e２．The  p a t h o l o g i c a l  c l a s s i f i c a t i o n  o f 
neuroendocrine tumors by World Health Organization 
classification［9, 10, 14］
Table 2. The pathological classification of neuroendocrine tumors by World Health 
Organization classification［9, 10, 14］  
WHO (2000/ 2004) WHO (2010) 
1. Well-differentiated endocrine tumor (WDET) 
1.1. Benign behavior 
   Confined to the pancreas, nonangioinvasive, < 2cm 
in size, ≦2 mitoses and ≦2% Ki-67 positive cells/ 
10HPF 
1.2. Uncertain behavior 
  Confined to the pancreas, ≧2cm in size, >2 mitoses 
and >2% Ki-67 positive cells/ 10HPF, or 
angioinvasive 
2. Well-differentiated endocrine carcinoma (WDEC) 
      Low grade malignant with gross local invasion  
and/or metastases 
Neuroendocrine tumor 
NET G1 
 
NET G2 
3. Poorly-differentiated endocrine carcinoma (PDEC)/  
small cell carcinoma, high grade malignant 
Neuroendocrine carcinoma 
 Large cell NEC 
 Small cell NEC 
NET; Neuroendocrine tumour, NEC; Neuroendocrine carcinoma 
 
－141－
Neuroendocrine tumor
Surgical strategies for P-NETs
Surgical treatment for P-NETs varies according 
to the site and size of the tumor, whether single or 
multiple, benign or malignant, and associated with 
multiple endocrine neoplasia type 1 or not. Patients 
with nonfunctioning P-NETs < 1.0 mm, which are 
occasionally found at autopsy, are certainly not 
candidates for treatment. Approximately 70%–90% of 
enlarging P-NETs have malignant features, such as 
invasion and metastases22）－28）. However, there are no 
definite indications regarding whether nonfunctioning 
P-NETs should be removed or observed based on 
size, since P-NETs are so rare that there is little 
evidence clarifying the size of tumors that should be 
treated29）－31）. Functional P-NETs such as insulinoma 
and gastrinoma should be treated surgically, even 
if the tumor is < 1 cm. Despite the small size, 
gastrinoma has malignant potential32）－35）. 
According to the ENETS guidelines, surgical 
resection is indicated for nonfunctioning P-NETs 
in patients who have symptoms, patients with a 
diagnosis of NET G2, and patients who desire to 
have surgery. They also recommend non-operative 
management as one of the therapeutic options for 
nonfunctioning P-NETs ≤ 2 cm if major pancreatic 
resection is required, and surgery is indicated if the 
tumor diameter increases by > 0.5 cm or to > 2 cm36）.
I n  c on t r a s t ,  a c c o r d i ng  t o  t h e  Na t i o n a l 
Comprehensive Cancer Network guidelines, surgery 
is generally indicated for all patients, but observation 
may also be an option for patients with small 
P-NETs detected incidentally depending on factors 
such as comorbidities, surgical risk, and tumor 
location37）. The Japanese guidelines proposed by the 
Classification/grade Ki-67 proliferation indexa Mitotic indexa
Well-differentiated PanNENs: pancreatic neuroendocrine tumours (PanNETs)
PanNET G1
PanNET G2
PanNET G3
< 3%
3-20%
> 20%
< 2
2-20
> 20
Poorly differentiated PanNENs: pancratic neuroendocrine carcinomas (PanNECs)
PanNEC (G3)
Small cell type
Large cell type
> 20% > 20
Mixed neuroendocrine –non-neuroendocrine neoplasm
a The ki-67 proliferation index is based on the evaluation of ൒ 500 cells in areas of higher nuclear 
labelling ( so-called hotspots). The mitotic index is based on the evaluation of mitoses in 50 high-
power fields (HPF: 0.2mm2 each) in areas of higher density and is expressed as mitoses per 10   
high power fields (2.0 mm2). The final grade is determined based on whichever index (Ki-67 or 
mitotic) places the lumen in the highest grade category. For assessing Ki-67, casual visual 
estimation (eyeballing) is not recommended: manual counting using printed images is advocated.
Table 3. 2017 WHO classification and grading of pancreatic neuroendocrine neoplasms 
(PanNENs) [22].
able３．2017 WHO cl ssificati n and grading of pancreatic 
neuroendocrine neoplasms (PanNENs) [22].
T-Primary Tumor M-Distant Metastasis
TX   Primary tumour cannot be assessed
T0    No evidence of primary tumour
T1    Tumour limited to pancreas**, less than 2cm in 
greatest dimension
T2 Tumour limited to pancreas**, 2cm or more 
but less than 4cm in greatest dimension
T3    Tumour limited to pancreas**, more than 4cm  
in greatest dimension or 
Tumour invading duodenum or bile duct
T4    Tumour perforates visceral peritoneum (serosa) 
or other organs or adjacent structures
M0 No distant metastasis
M1    Distant metastasis
M1a  Hepatic metastasis only
M1b  Extrahepatic metastasis only
M1c  Hepatic and extrahepatic metastases
Stage
Stage Ⅰ T1 N0 M0
Stage Ⅱ T2, T3 N0 M0
Stage Ⅲ T4
Any T
N0
N1
M0
M0
N- Regional Lymph Nodes Stage Ⅳ Any T Any N Any M
NX    Regional lymph nodes cannot be assessed
N0    No regional lymph node metastasis
N1    Regional lymph node metastasis
*The TNM classification of PanNECs follows the 
criteria for classifying ductal adenocarcinomas.
** This includes invasion of the peripancreatic
adipose tissue.
Table 4. TNM classification of tumours of the neuroendocrine pancreas* [22].Table４．TNM classification of tumours of the neuroendocrine pancreas* [22].
－142－
Tezuka, Kimura, Hirai, Sugawara, Watanabe, Ashitomi, Nozu, Takahashi
Japan Neuroendocrine Tumor Society recommend 
that all patients with nonfunctioning P-NETs are 
candidates for surgery regardless of tumor diameter 
as long as they are managed in the hospital where 
pancreatic surgery can be done safely and do not 
have contraindications to surgery such as severe 
comorbidities38）.
Considering that some nonfunctioning P-NETs 
≤ 2 cm are still highly malignant with metastatic 
potential39）－41）and that analyses using the United 
States National Cancer Database have shown that 
surgical resection of nonfunctioning P-NETs ≤ 2 cm 
improves survival40），42）, surgery should be indicated 
for all nonfunctioning P-NETs. However, in studies 
that followed patients with nonfunctioning P-NETs 
≤ 2 cm（median or mean size: 10 to 14 mm）
that were asymptomatic（i.e., no epigastric pain, 
jaundice, pancreatitis, or symptoms associated 
with excessive hormone secretion）and had no 
invasion of peripancreatic tissue or lymph node or 
extrahepatic metastasis on imaging for a period of 
31 to 45 months（median or mean），tumor growth 
of ≥ 20% was reported in only 0% to 13% of patients 
and no metastases or disease-specific deaths were 
reported, even in patients who underwent surgery 
after observation43）－46）. In a Japanese study that 
followed 19 patients with nonfunctioning P-NETs 
with a median size of 12 mm for a median period of 
45 months, five-year progression-free survival was 
83%47）. The results of these studies suggest that 
observation with careful monitoring of progress 
may be feasible for a select group of patients with 
tumors ≤ 2 cm. Several studies have concluded that 
patients with nonfunctioning P-NETs < 15 mm, 
many of which are NET G1, are ideal candidates for 
observation46），47）. Moreover, Zhang et al. found that 
although surgical resection improves survival in 
patients with nonfunctioning P-NETs ≥ 15 mm, the 
significance of surgery is unclear in patients with 
nonfunctioning P-NETs < 15 mm48）. Using size as an 
indicator, a cutoff of 15 mm may be one means of 
determining whether observation is also an option. In 
addition, studies have shown that survival outcomes 
are significantly worse for G2/3 nonfunctioning 
P-NETs ≤ 2 cm than for G1 tumors ≤ 2 cm and 
improved survival can be anticipated with surgical 
resection in patients with G2/3 nonfunctioning 
P-NETs ≤ 2 cm49），50）. As such, surgery should always 
be performed for P-NET G2/3 patients regardless of 
tumor size. 
Surgical treatment of primary tumors
In the WHO classifications published in 2000９）and 
200410）, NETs were classified into benign behavior 
or uncertain behavior and well-differentiated NEC 
or poorly differentiated NEC. However, the WHO 
classification published in 2010 emphasized grade 
as recommended by ENETS11），12）, and NETs were 
classified into NET G1, NET G2, or NEC（G3）based 
on mitotic count and Ki-67 labeling index14）. The 
prognosis of Grade 2/3 P-NETs is significantly worse 
than that of Grade 1 P-NETs17），18），51）－55）. Even if the 
tumor is small, radical surgery with regional lymph 
node dissection should be performed for Grade 2/3 
P-NETs52），56）. 
Determination of TNM classification and grade is 
important in deciding on a surgical strategy for the 
primary tumor because these are risk factors for 
postoperative recurrence.
Predictors of lymph node metastasis and grade
（Tables 5, 6）
Tables 5 and 6 show predictors of lymph node 
metastasis41），57）－80）and grade46），50），67），69），71），72），78），79），81）－94）. 
The relationship between tumor diameter and 
lymph node metastasis has been well researched. 
Many studies have shown that the rate of lymph 
node metastasis is significantly higher for tumors 
> 15 to 20 mm41），58）－69）. Tumors > 15 to 20 mm are 
also more likely to be Grade 2/346），50），67），69），84）－90）, and 
thus tumor diameter is an important predictor of 
grade as well as lymph node metastasis. However, 
several studies have shown that tumor diameter 
is not an independent predictor of lymph node 
metastasis41），60），61），69）. Some studies have shown that 
even P-NETs < 10 mm are accompanied by lymph 
node metastasis in 10% to 30% of patients39），40），41），65）, 
and this may be partially attributable to the presence 
of patients with lymph node metastasis regardless 
of tumor diameter. Consequently, it is important to 
evaluate factors other than tumor diameter.
Nodal features suggest ive of  lymph node 
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Table 5. Reported predictive factors for lymph node metastasis of P-NETs 
 Reference No. 
Statistically significant difference 
Presence Absence 
Category Ⅰ
Lymph node 
Enlargement (൒ 1 cm)/hypervascularization (CT) 
A short axis measuring > 1 cm/abnormal round  
morphology/central necrosis (CT) 
Tumor size 
>/൒ 15 mm  
> 17 mm/> 18 mm 
>/൒ 20 mm 
Tumor enhancement pattern 
Hypoenhancement on arterial phase (CT)     
Hetero/hypo-attenuation in the late arterial  
phase (30 s) (CT) 
Iso/hypo-attenuation in the pancreatic phase (44 s) 
  Tumor to pancreas contrast ratio on portal 
  venous phase (75 s) < 1.238 (CT) 
Main pancreatic duct involvement (MRCP/CT) 
Tumor shape irregular (CT) 
Laboratory findings 
Neutrophil to lymphocyte ratio (NLR) ൒ 2.056 
Pathological factor 
Grade G2/G3 
      
Poorly/moderately differentiation 
Lymph vascular invasion 
Positive CK19 expression 
  No hormonal expression for 
  immunohistochemical study 
  Gastrin/serotonin expression for  
immunohistochemical study 
57[UM] 
58[UM] 
41[U]/ 59[U], 60[U] , 61[U] 
62[U]/ 63[UM] 
64[U], 65[UM], 66[UM] / 67[U] 
70[U] 
60[UM]  
71[U] 
58[UM] 
61[UM] 
72[U] 
73[UM] 
41[U], 57[UM], 60[U], 61[U],  
63[U], 74[UM], 
68[UM] 
41[U], 68[U] 
75[U], 76[U] 
77[U] 
77[U] 
41[M], 60[M], 61[M] 
68[U], 69[M] 
41[M], 60[M], 61[M] 
41[M] 
Category Ⅱ
Symptomatic (Non-functioning tumor) 
Tumor location Pancreatic head 
Vascular invasion (CT) 
Tumor margin poorly defined (CT) 
Intratumoral calcification (CT) 
Tumor thrombus 
Perineural invasion 
68[U], 74[UM], 78[U], 79[U] 
41[U], 57[U], 63[U], 66[UM],  
69[M] 
58[U] 
58[U] 
80[UM] 
73[U] 
68[U] 
69[M], 57[U] 
41[M], 57[M], 58[U], 60[U], 61[U], 
63[M], 65[U], 74[U], 80[U] 
58[M] 
58[M] 
58[U], 60[U] 
73[M] 
68[M] 
Definitions of Categories I and II: 
Category I: Factors identified as potential predictors of lymph node metastasis by statistical or clinical analysis 
Category II: Potential predictors of lymph node metastasis on which further research is warranted 
U: univariate analysis; M: multivariate analysis 
Table５．Reported predictive factors for lymph node metastasis of P-NETs
metastasis have also been investigated. Partelli et al. 
found that enlargement of the lymph nodes to ≥ 1 cm 
and/or hypervascularization of peripancreatic lymph 
nodes on contrast-enhanced CT were independent 
predictors of lymph node metastasis57）. Choi et al. 
found that a nodal short axis diameter greater 
than1cm, an abnormal round morphology, and central 
necrosis were independent predictors of lymph node 
metastasis58）. 
Many studies have shown that tumor contrast 
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enhancement pattern is a predictor of lymph node 
metastasis and NET G2/3. A typical NET G1 
exhibits homogeneous tumor staining reflecting 
hypervascularity in the early arterial phase or 
late arterial phase（pancreatic parenchymal 
phase）（20 to 44 s after injection of contrast 
medium）60），71），95）－99）. In addition, they typically exhibit 
peak contrast enhancement in the early arterial（20 
to 26 s）or late arterial（30 to 45 s）phase71），97），100）, 
followed by contrast medium washout in the portal 
venous phase（65 to 75 s）or equilibrium phase 
（180 s）71），97），99）. In contrast, highly malignant tumors
（NET G2/3）do not exhibit tumor staining in the 
arterial phase60），71），99），101）, and exhibit peak contrast in 
the portal venous phase or equilibrium phase67），97），102）. 
Invasion of the main pancreatic duct61），89），90）, 
invasion of peripancreatic tissue85），86），90）, and vascular 
invasion84）－87），90）have also been identified as predictors 
of lymph node metastasis or NET G2/3.
These studies indicate that it is necessary to 
consider not only tumor diameter but also features 
of peripancreatic lymph nodes, tumor contrast 
Table６．Reported predictive factors for Grade 2/3 P-NETsTable 6. Reported predictive factors for Grade 2/3 P-NETs 
 Reference No. 
Statistically significant difference 
Presence Absence 
Category Ⅰ   
Diagnosis of G2/3 by EUS-FNA 81, 82, 83  
Tumor growth (൒ 20% or 5 mm increase in size) 46[U]  
Imaging findings 
 Tumor size 
  ൒ 15 mm/> 17.5 mm 
  >/൒ 20 mm 
 
  ൒ 30 mm 
 
 
46[UM]/84 
50[U], 85[U], 69[M],86[U],  
87[U]/67[U], 88[U], 89[UM]  
90[U] 
 
Tumor enhancement pattern 
Non-homogenous hyper-attenuation on arterial phase 
(20-30 s)   
Iso/hypo-attenuation in the pancreatic phase (44 s)    
Tumor to pancreas contrast ratio on arterial phase (CT) 
< 1.1 (Predictive factor for grade 2/3)   
Late contrast enhancement  
(peak attenuation observed in the venous phase) (CT) 
91[U] 
 
71[U] 
67[U]  
 
67[U]  
 
Peripancreatic tissue invasion (MRI/CT) 
Vascular invasion (MRI/CT) 
MPD involvement (MRI/EUS) 
86[U], 90[U]/85[UM] 
84[U], 86[U], 90[U] /87[U], 85[UM] 
90[U]/89[UM] 
 
88[U] 
ADC value (MRI) ≤ 1.22/1.21/0.930×103 mm2/s   
ADC ratio [ADC value of the tumor (solid portion)/  
ADC value of the parenchyma] < 0.94 
84/ 92/ 93 
91 
 
Category II 
Symptomatic (non-functioning tumor) 78[U],79[U] 69[M] 
Heterogenous enhancement (MRI/ CT) 
MPD dilatation ൒4 mm (MRI/CT) 
 
Ill-defined borders (MRI/CT) 
Tumor shape irregular/lobular (CT/EUS) 
Lymphadenopathy (൒10 mm) (with irregular margin and  
 heterogenous enhancement) (CT)  
Internal echo pattern (EUS)   heterogenous  
84[U], 94[U] / － 
86[U], 94[U]/87[U], 85[U] 
 
84[U], 94[U]/85[U] 
72[U], 85[U], 91[U]/ － 
85[U], 87[U] 
 
89[U] 
92[U]/67[U], 86[U], 88[U] 
84[U],90[U], 92[U]/85[M], 
88[U], 91[U] 
90[U], 94[U]/85[M], 88[U] 
85[M]/89[U] 
85[M] 
 
89[M] 
Definitions of Categories I and II: 
Category I: Factors identified as potential predictors of Grade 2/3 P-NETs by statistical or clinical analysis 
Category II: Potential predictors of Grade 2/3 P-NETs on which further research is warranted 
U: univariate analysis; M: multivariate analysis 
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enhancement patterns, and invasion of the main 
pancreatic duct, invasion of peripancreatic tissue, 
and vascular invasion when determining tumor 
malignancy.
Endoscopic ultrasound-guided f ine needle 
aspiration biopsy（EUS-FNA）is a method for 
grading tumors by direct collection of tumor 
tissue. However, one flaw of this method is that it 
underestimates the grade of NET G2/3 tumors with 
internal heterogeneity as the less malignant NET G1. 
Nevertheless, studies have shown that a preoperative 
pathological diagnosis of NET G2/3 by EUS-
FNA often matches the postoperative pathological 
diagnosis81）－83）.
Jung et al. found that tumors that grow by at 
least 20% or 5 mm in diameter are more likely to be 
NET G2/3, and that tumors that grow rapidly during 
observation must be treated as NET G2/3 as well46）.
Many studies have shown that NET G1 exhibit 
high apparent diffusion coefficient（ADC）values 
on diffusion-weighted magnetic resonance imaging
（MRI）, and cutoff points ranging from 0.930 to 1.22 
were found to have clinical utility84），92），93）. In addition, 
Toshima et al. examined the ratio of ADC values of 
tumors and pancreatic parenchyma of the proximal 
side of the tumor to control for variation in ADC 
values by MRI scanner, and found that tumors 
with an ADC ratio（ADC value of the tumor/ADC 
value of the pancreatic parenchyma）of < 0.94 were 
often graded as NET G2/3, and ADC ratio was an 
independent predictor of grade91）.
Another study showed that SUVmax on FDG-
PET is high in NET G3, and a cutoff value of 2.5 has 
clinical utility for differentiating between NET G3 
and G1/2 patients103）. Although differences between 
PET scanners may influence FDG-PET results as 
well, it can at least be assumed that tumors with low 
SUVmax are less malignant.
Some studies have shown that patients with 
nonfunctioning P-NETs who exhibit symptoms 
such as abdominal pain, jaundice, and weight 
l oss  are  s ign i f i cant ly  more  l ike ly  to  have 
lymph node metastasis or NET G2/368），74），78），79）. 
However, other studies have shown no significant 
difference57），69）. Findings common to all these studies 
are that symptomatic nonfunctioning P-NETs often 
have a large tumor diameter and more advanced 
stage, with differences in these features manifesting 
as differences in grade of malignancy. However, 
Birnbaum et al. found that symptomatic patients, 
even those with tumors < 2 cm, were significantly 
more likely to have NET G2 or perineural invasion, 
and that lymph node metastasis also tended to be 
more common in symptomatic patients（25% vs. 9%, 
P = 0.19）78）. In a study of 16 symptomatic patients 
with nonfunctioning P-NETs ≤ 2 cm, Sallinen et al. 
found that 7 patients with lymph node metastasis or 
liver metastasis had obstruction of the bile duct or 
main pancreatic duct50）. Particular care is necessary 
in the evaluation of symptomatic patients with bile 
duct or main pancreatic duct invasion, even if the 
tumor size is ≤ 2 cm.
Although many studies have shown that lymph 
node metastasis is significantly more common 
in tumors of the pancreat ic head41），57），63），66），69）, 
many other studies have shown no significant 
difference６），41），57），58），60），61），63），74），80）. As no study has 
shown that tumors of the pancreatic head are more 
likely to be NET G2/3, it is possible that lymph node 
metastasis of the tumors of the pancreatic head are 
more likely to occur than that of the tumors of the 
body or tail, if they are the same grade. At this point, 
it is necessary to evaluate lymph node metastasis 
risk comprehensively with consideration to other risk 
factors rather than relying on tumor location alone.
Although the extent of cystic component is not 
an independent predictor of NET G2/385），91）, tumors 
with lymph node metastasis and NET G2/3 rarely 
have a large cystic component（≥ 50% of total tumor 
size）104），105）. Differential diagnosis from cystic tumors 
such as IPMN and MCN is also challenging for these 
types of NETs104）.
Selection of surgical procedure（Tables 7，8，9）
There are currently no clear indications for 
organ-preserving resection, such as enucleation and 
spleen-preserving distal pancreatectomy（SpDP）, in 
patients with P-NETs57），106）－111）.
Standard pancreatectomy with lymph node 
dissection is the treatment of choice when the tumor 
diameter is over 2 cm or lymph node metastasis 
or Grade 2/3 tumor is suspected preoperatively. 
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Essential ly, pancreaticoduodenectomy is the 
treatment of choice for tumors of the pancreatic 
head, and distal pancreatectomy with splenectomy is 
the treatment of choice for tumors of the pancreatic 
body and tail（Tables 7，8）.
Standard pancreatectomy with lymph node 
dissection is also selected for functioning tumors 
other than insu l inomas（Table  9）32）－35），112）－115）. 
Gastrinomas are particularly malignant, and 
even  sma l l  g a s t r i n omas  h ave  me t a s t a t i c 
≧3mm
Consider additional radical surgery or follow-up, depending on the initial surgery
Positive
Surveillance depending on pathological findings
Negative
Distance from main pancreatic duct
Tumor size ＜20mm
・Predictive factors for NET G2/ NEC (G3)
・Predictive factors for lymph node metastasis
NegativePositive
Tumor capsule ＜3mm
《Radical surgery including  
regional lymphadenectomy》
・Pancreatoduodenectomy
・Distal pancreatectomy with 
splenectomy
・ Total pancreatectomy
Insulinoma
Positive
Negative
《Organ-preserving surgery ± lymph node sampling》
・ Spleen-preserving distal pancreatectomy
・ Central pancreatectomy
・ Duodenum-preserving pancreatic head resection
《Intraoperative frozen section diagnosis》
Lymph node metastasis
Enucleation
±
lymph node sampling
Negative
Tumor size ≧20mm
Positive
《Pathological findings of resected specimen》
Risk factors of recurrence
Table８
Consider additional radical surgery or follow-up, depending on the initial surgery
Positive
Surveillance depending on pathological findings
《Pathological findings of resected specimen》
Risk factors of recurrence
Negative
Distance from main pancreatic duct
Tumor size ＜20mm
NegativePositive
Tumor capsule ＜3mm
《Radical surgery including  
regional lymphadenectomy》
・Pancreaticoduodenectomy
・Distal pancreatectomy with 
splenectomy
・ Total pancreatectomy
Positive
Negative
《Organ-preserving surgery ± lymph node sampling》
・ Spleen-preserving distal pancreatectomy
・ Central pancreatectomy
《Intraoperative frozen section diagnosis》
Lymph node metastasis
Enucleation
±
lymph node sampling
Negative
Tumor size ≧20mm
Positive
Small (＜1cm) tumor in the pancreatic body or tail
≧3mm
Nonfunctioning pancreatic 
neuroendocrine tumor
・Predictive factors for NET G2/ NEC (G3)
・Predictive factors for lymph node metastasis
Table７
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potential33），35）. Insulinomas ≤ 2 cm with no malignant 
features are almost always benign and are 
associated with favorable postoperative survival, 
so patients with such tumors are good candidates 
for organ-preserving surgery（Table 8）116）. Studies 
in which hormone production was evaluated by 
immunohistochemical study have shown that 
glucagon- and somatostatin-producing tumors are 
less likely to metastasize to the lymph nodes than 
gastrin- or serotonin-producing tumors77）. However, 
glucagonomas and somatostatinomas that cause 
symptoms due to overproduction of hormones are 
often first detected in patients with advanced disease 
that has already metastasized to the liver112）－114）. 
Organ-preserving surgery is indicated for patients 
without risk factors such as lymph node metastasis
（Table 5）or NET G2/G3（Table 6）. In specific 
terms, tumors that meet criteria such as size of 
< 15 mm, no peripancreatic lymph node features 
suggestive of lymph node metastasis, round or oval 
tumor morphology, well-defined tumor margins 
with no invasion of the main pancreatic duct or 
peripancreatic tissues, homogeneous tumor staining 
pattern on arterial-phase dynamic CT, low ADC 
relative to the pancreatic parenchyma on diffusion 
MRI, and lack of 20% or 5-mm growth during 
observation are relatively good candidates for organ-
preserving surgery.
However, even patients with tumor diameter < 10 
mm may have lymph node metastasis39）－41），65），and 
conversely, some patients with a tumor diameter 
of 15 to 20 mm may still be candidates for organ-
preserving surgery as long as they do not have any 
other poor prognostic predictors such as lymph node 
metastasis or NET G2/360），61）. Consequently, it is 
probably necessary to pay attention to factors other 
than tumor diameter as well.
One study on insulinomas found no difference in 
grade between tumors that did not show the typical 
tumor staining pattern in the arterial phase with 
those that did show the typical contrast pattern117）. 
This indicates that grading of insulinomas by 
contrast pattern alone should be avoided in favor 
of consideration alongside other findings when 
determining a surgical strategy.
Insulinomas < 20 mm that are located at the 
pancreatic margin far from the main pancreatic 
duct, are covered by a capsule, and have no other 
malignant features besides tumor diameter are 
good candidates for enucleation29），116）. SpDP or 
middle pancreatectomy are indicated for tumors 
of the pancreatic body or tail that are close to the 
main pancreatic duct, because injury of the main 
pancreatic duct may cause postoperative refractory 
pancreatic fistula and abdominal abscess. In that 
situation, duodenum-preserving pancreatic head 
resection（DPPHR）should be considered for tumors 
of the pancreatic head29）. Nonfunctioning tumors of 
the pancreatic body or tail without risk factors such 
as lymph node metastasis or NET G2/3 that are 
far from the main pancreatic duct, are ≤ 1 cm, and 
are asymptomatic on detection are relatively good 
candidates for enucleation38），65），118）. 
SpDP with conservation of the splenic artery and 
vein（Kimura’s method）does not include adequate 
dissection of the splenic hilar lymph nodes, but the 
same extent of dissection performed in standard 
surgery is technically feasible for dissection of lymph 
nodes surrounding the pancreatic body. SpDP may 
also be indicated for some nonfunctioning tumors of 
the pancreatic body that are > 15 mm in diameter 
but have no other malignant features.
Advantages o f  organ -preserv ing surgery 
i n c l u d e  p r e v e n t i o n  o f  p o s t o p e r a t i v e 
d i a b e t e s 109），119），p r e s e r v a t i o n  o f  p a n c r e a t i c 
exocrine function109），119），120），and reduced risk of 
i n f e c t i o n 120），121）,  n ew  ma l i g n a n c i e s 123），and 
Gastrinoma
Glucagonoma
Somatostatinoma
VIPoma
《Radical surgery including lymphadenectomy》
・Pancreatoduodenectomy
・Distal pancreatectomy with splenectomy
・Total pancreatectomy
Table９
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thromboembolism122），124）. Consequently, it should be 
performed whenever possible when indicated.
As organ-preserving surgery does not include 
adequate lymph node dissection, sampling dissection 
of the peripancreatic lymph nodes should be 
performed intraoperatively when enlarged lymph 
nodes are detected around the tumor and standard 
surgery performed if metastasis is suspected.
Laparoscopic surgery has been widely performed 
for pancreatic neoplasms. The postoperative 
morbidity of laparoscopic surgery is comparable to 
that of open surgery125）－127）.
Although different institutions must establish 
their own eligibility criteria, laparoscopic surgery is 
generally a good choice for less malignant tumors for 
which organ-preserving surgery would be indicated.
Risk factors for recurrence after primary tumor 
resection（Table 10）
Table 10 shows risk factors for recurrence 
after primary tumor resect ion41），50），57），68），74），78），94）， 
128）－133）. Recurrence of nonfunctioning tumors after 
enucleation or middle pancreatectomy has been 
reported in patients with characteristics such 
as NET G2 and lymph node metastasis110），119）. 
Recurrence of insulinomas has also been reported 
in patients with risk factors for recurrence such as 
NET G2, lymph node metastasis, and lymphovascular 
Table 7. Previously reported risk factors for recurrence after resection of the primary tumor without distant 
metastasis. 
Reference No. 
Statistically significant difference 
Presence Absence 
Category Ⅰ   
Non-insulinoma 
Imaging findings 
Tumor size ൒ 4 cm 
Bile duct obstruction 
Pancreatic duct obstruction 
Pathological findings 
Ki-67 index   
൒ 2% 
> 20% 
Grade (WHO): G2/3 
Final resection status: R1 
Lymph node metastasis 
Angioinvasion 
Tumor necrosis 
Well differentiated endocrine carcinoma 
  (WHO 2004) 
Poorly/moderately differentiation 
T stage: T3/4 (ENETS) 
128[UM] 
57[U], 68[U] 
129[UM] 
129[UM] 
128[UM] 
41[UM] 
50[UM], 57[UM], 94[U], 128[U], 
130[U], 78[UM] 
57[U], 131[UM] 
41[UM], 50[U], 57[UM], 74[UM], 
128[UM], 130[U], 131[U] 
57[U], 74[UM], 132[U] 
130[U] 
130[U] 
68[U], 132[U] 
128[UM] 
57[M] 
50[M], 68[U] , 78[M], 131[M] 
132[U] 
57[M] 
Category Ⅱ
Symptomatic (non-functioning tumor) 
Tumor size > 2 cm 
Perineural invasion 
Lymphovascular invasion 
Elevation of CA19-9 
78[U], 133[M] 
74[U] 
57[U], 74[U], 130[U], 131[U] 
130[U] 
74[U] 
50[U], 57[U], 74[U], 78[M] 
68[U], 74[M] 
57[M], 68[U] , 74[M] 
68[U], 131[U] 
74[M] 
Definitions of Categories I and II: 
Category I: Factors identified as potential predictors of recurrence by statistical or clinical analysis 
Category II: Potential predictors of recurrence on which further research is warranted 
U: univariate analysis; M: multivariate analysis 
Table10．Previously reported risk factors for recurrence after resection of the primary tumor without distant 
metastasis.
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invasion134），135）. This indicates that depending on 
the surgical strategy（particularly enucleation or 
middle pancreatectomy），it may be necessary to 
consider and discuss the possibility of additional 
radical surgery with patients who have risk factors 
for recurrence such as lymph node metastasis, NET 
G2/3, moderately or poorly differentiated NETs, 
vascular invasion, or R1 resection as a result of 
histopathological evaluation after organ-preserving 
surgery. Potential cure through radical surgery is 
preferable to death resulting from local recurrence 
following organ-preserving surgery.
Surgical techniques for P-NETs
There are various surgical techniques for tumor 
enucleation and SpDP. Lymph node dissection should 
be performed for cases with lymph node metastases 
or obvious invasive findings. Pancreatoduodenectomy 
with combined portal vein resection or distal 
pancreatectomy with splenectomy is selected for 
advanced P-NET cases.
Enucleation for P-NETs
Enucleation is usually indicated for benign 
P-NETs. In particular, insulinomas, which are often 
diagnosed when < 2 cm, especially those measuring 
approximately 1 cm and projecting hemispherically 
from the surface of the pancreas and have a fibrous 
capsule surrounding the tumor29），136）, tend to be 
resected using enucleation. 
Enucleat ion can cause injury to the main 
pancreatic duct if the distance between the tumor 
and the main pancreatic duct is very small, and 
suturing of the pancreatic parenchyma after 
enucleation can cause stenosis of the main pancreatic 
duct. These injuries may result in postoperative 
refractory pancreatic fistula and abdominal abscess.
In such cases, SpDP with conservation of the 
splenic artery and vein（Kimura’s method）136）－138）and 
segmental pancreatectomy109）are also indicated for 
tumors of the body and tail of the pancreas. DPPHR 
may also be considered if the tumor is located deep 
in the head of the pancreas.
Preoperative computed tomography（CT）, 
angiography, and EUS should be used to determine 
the presence of infiltration to neighboring organs and 
capsule.
The number of multiple NETs in the pancreas 
and location of the tumors should be diagnosed 
preoperatively using CT, MRI, EUS, selective 
arterial calcium injection（SACI）test, and other 
modalities. Endoscopic ultrasonography is somewhat 
useful in detecting small P-NETs like insulinoma. 
The sensitivity of EUS for insulinoma is 83%–94%, 
and this increases to 96%–100% if EUS is combined 
with CT and MRI127），139）－141）. A SACI test should be 
applied if the tumor cannot be detected with these 
modalities.
Advances in preoperative diagnostic modalities 
have allowed the detection of small P-NETs. 
Palpation and intraoperative ultrasonography should 
be performed to confirm the results of a preoperative 
diagnosis. An intraoperative diagnosis may be less 
accurate than a preoperative diagnosis, and requires 
a wider surgical field. This could lead to organ injury. 
Therefore, only tumors that are accurately diagnosed 
preoperatively should be resected29）.
Preoperative stenting to the pancreatic duct 
through the papilla is useful for enucleation when 
the tumor is very close to the main pancreatic duct. 
Such stenting simplifies intraoperative detection of 
the main pancreatic duct. The surgeon can perform 
enucleation of the tumor safely without damaging the 
pancreatic duct142）. Another technique uses injection 
of dye into the main pancreatic duct, which enables 
the surgeon to note leakage from the pancreatic 
branch duct. This technique requires the surgeon 
to be very familiar with the surgical anatomy of the 
pancreas143）.
Spleen-preserving distal pancreatectomy with 
conservation of the splenic artery and veins（SpDP）
Preservation of the spleen in distal pancreatectomy 
has recently attracted considerable attention. Since 
the first trial and success with conservation of the 
splenic artery and vein for tumors of the pancreas 
and chronic pancreatitis, this procedure（Kimura’s 
procedure）136），137）has been performed very frequently. 
Splenic preservation can reduce the risk of 
hematological abnormalities, such as the elevation of 
serum platelet counts, thrombotic complications, and 
overwhelming postsplenectomy infection137），144）－146）. 
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Enucleation is a common first-line therapy for 
benign P-NETs. However, enucleation can lead to 
injury of the main pancreatic duct if the distance 
between the tumor and the main pancreatic duct 
is very small, and so suturing of the pancreatic 
parenchyma after enucleation can cause stenosis of 
the main pancreatic duct. These injuries may result 
in postoperative refractory pancreatic fistula and 
abdominal abscess. SpDP with conservation of the 
splenic artery and vein（Kimura’s procedure）
may be desirable in such cases. Enucleation is also 
indicated if invasion to the pancreatic parenchyma is 
not clearly observed on imaging studies.
Surgical strategies for primary tumor with 
unresectable liver metastasis
Some reports have indicated a positive stance 
toward primary tumor resection for patients with 
P-NETs who have unresectable distant metastases 
because it is expected that this can improve the 
prognosis and quality of life of patients who have 
symptoms such as biliary and gastrointestinal 
obstruction, gastrointestinal bleeding, and abdominal 
pain27），147）－150）. Furthermore, primary tumor resection 
makes it easier to select liver-targeted therapy, such 
as transarterial embolization（TAE）or transarterial 
chemoembolization（TACE）. However, some 
authors have indicated that the effect of primary 
tumor resection in patients with unresectable 
liver metastasis is merely palliative, rather than 
improvedoutcome151），152）. Therefore, resection of the 
primary tumor in patients with unresectable liver 
metastasis from P-NETs is controversial. 
Bloomston et a l .  have a lso reported that 
cytoreductive surgery at primary tumor resection
（R2 resection）did not improve outcome, and 
in fact increased the incidence of postoperative 
complications153）. It has also been reported that 
primary tumor resection should be avoided if liver 
metastasis shows a poorly differentiated histology, a 
Ki-67 labeling index of > 10%, and involves > 50% of 
the whole liver, because the outcome after primary 
tumor resection is very poor in such situations151），154）.
Resection of the primary tumor may be indicated 
for resectable symptomatic tumors or tumors that 
are considered likely to become symptomatic in the 
near future, on the basis of prognostication from 
the extent of liver metastasis and the degree of 
tumor differentiation. In such cases, prophylactic 
cholecystectomy should be performed to prevent 
necrosis of the gallbladder following TAE/TACE. 
Palliative surgery such as a bypass operation may be 
indicated for bowel obstruction due to unresectable 
primary P-NETs.
Surgical treatment for liver metastasis
Hepatic resection combined with or without 
radiofrequency ablation is generally the first-line 
therapy for liver metastasis of P-NETs if there 
is no peritoneal dissemination or extra-abdominal 
metastasis, because they are usually slow-growing 
tumors155）－157）. Recently, the usefulness of 68Ga-
DOTATOC-PET/CT for detection of distant 
metastasis and staging has been reported158），159）. The 
5- and 10-year survival rates for patients treated 
surgically for liver metastasis from NETs, including 
P-NETs, which account for 30-50% of all NETs in 
previous series, have been 61-86% and 35-50%155），157），
160）－167）, respectively.
There has so far been no randomized control 
study comparing surgical with non-surgical 
treatment for resectable liver metastasis from 
NETs. However, liver resection has been performed 
for resectable liver metastasis as first line-therapy, 
because the prognosis of patients who undergo 
liver resection is better than that of patients who 
do not, with 5-year survival rates of 0-40%167）－170）. 
Recently, the Surveillance, Epidemiology, and End 
Results program of the National Cancer Institute 
United States, has demonstrated that the prognosis 
of patients with distant metastasis from P-NETs, for 
whom surgery was recommended but who declined, 
was significantly worse than that of patients who 
underwent surgery171）.
P a r t i a l  r e s e c t i o n ,  s egmen t a l  r e s e c t i o n , 
subsegmental resection, and lobectomy of the liver 
can also be considered based on the site and number 
of liver metastases. Combination chemotherapy 
with cisplatin and etoposide or irinotecan, instead 
of hepatectomy, is the first-line therapy for liver 
metastasis of NEC as defined by the 2010 WHO 
classification172）.
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Frilling et al. reported that prognosis and biological 
malignancy differed according to the localization and 
number of liver metastases158），173）, and the ENETS 
guidelines suggest a therapeutic strategy that is 
based on this concept172）. 
The 5-year recurrence rate of liver metastasis 
after surgical treatment is very high, exceeding 80%. 
Most such recurrences occur within 2 years after 
surgery, and the most common sites are the liver, 
bone, lung, lymph nodes, peritoneum, and brain, 
the liver accounting for 80-90% of all recurrence 
sites161），163）－165），167），168），174）. Elias et al. reported that the 
preoperative detection rate for liver metastases by 
somatostatin receptor scintigraphy, CT, MRI, and 
abdominal ultrasonography was < 50% in comparison 
with final histological examination of liver specimens 
that had been systematically cut into 3- to 4-mm 
slices175）. Control of such micrometastases is a major 
problem to be resolved in the future, in order to 
improve liver surgery outcomes176）.
Simultaneous resection of primary P-NETs and 
liver metastasis carries a potential risk of fatal 
morbidity, such as bleeding due to pancreatic fistula 
and liver failure, and requires careful treatment 
decision-making. Sarmiento et al. reported that 
the rates of major morbidities such as bile leakage 
and pancreatic fistula, and mortality after distal 
pancreatectomy combined with liver resection 
were 18% and 0%, respectively160）. Kianmanesh et al. 
reported two-step surgery for synchronous bilobar 
liver metastasis from digestive NETs including 
P-NETs of the distal pancreas. According to that 
report, at first-step surgery, distal pancreatectomy, 
partial resection of the left hepatic lobe, and 
ligation of the right portal vein were performed. 
For second-step surgery 8 weeks later, a right 
or extended right hepatectomy was performed. 
Using this strategy, morbidity and mortality rates 
were approximately 20% and 0%, respectively177）. 
With adequate surgical planning and in specialized 
centers, surgical treatment of synchronous liver 
metastasis and P-NETs of the distal pancreas 
may be performed safely. In relation to combined 
surgery, pancreatoduodenectomy, and extended liver 
surgery, one study found that combined surgery was 
associated with a high mortality rate of 38%（3/8 
cases）178）. In this situation, careful decision-making 
about surgical indications is necessary.
Complete surgical resection is often difficult for 
liver metastasis, since 86% of patients with liver 
metastasis already have unresectable multiple 
liver metastases and extrahepatic metastases179）. 
Fo r  un r e s e c t ab l e  l i v e r  me t a s t a s e s ,  l i v e r 
transplantation, transarterial chemoembolization/ 
embol izat ion 180），181）systemic chemotherapy 182）, 
biotherapy such as somatostatin analogue and 
interferon-α183）, peptide receptor radionuclide 
therapy（PRRT）184）and targeted therapy185），186）have 
been selected based on the presence or absence of 
extrahepatic metastasis, tumor proliferative activity, 
and somatostatin receptor status134），155），169）. It has 
been reported that a small number of patients with 
an inoperable primary tumor and metastasis can 
achieve down-sizing and curative resection by the 
use of PRRT159），184）.
Liver transplantation for patients with liver 
metastases from P-NETs is indicated if the 
metastases are unresectable and no extrahepatic 
metastas is is  present ,  a l though subsequent 
recurrence rates are very high172）. Lehnert et 
al. reviewed 103 patients who underwent liver 
transplantation for liver metastasis from NETs and 
reported that their 5-year overall and recurrence-free 
survival rates were 47% and < 24%, respectively; 
the postoperative mortality rate within 60 days 
after liver transplantation was 14%187）. Favorable 
prognostic factors after liver transplantation are 
a well-differentiated tumor histology, positive 
immunoreactivity for E-cadherin, a Ki-67 labeling 
index of < 5-10%, and liver metastasis involving 
< 40% of total liver volume188）－190）. Le Treut et al. 
reported that liver transplantation for P-NETs is 
associated with poor prognosis, along with upper 
abdominal exenteration, liver transplantation 
for liver metastasis from duodenal NETs, and 
hepatomegaly191）. In a review of liver transplantation 
for liver metastasis from P-NETs, however, Máthé et 
al. concluded that liver transplantation for patients 
< 55 years of age who did not undergo resection 
of the primary tumor and liver transplantation 
simultaneously had a relatively good outcome, 
with a 5-year survival rate of 61%192）. Thus, liver 
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transplantation may improve outcomes for selected 
patients.
Cytoreductive hepatic surgery, which removes 90% 
of liver metastases, may be indicated for hormonal 
symptoms that are resistant to medical therapy, to 
reduce the amount of hormone and improve clinical 
symptoms and prognosis, and may even increase 
long-term survival193）－195）. The rate of remission 
of hormonal symptoms by cytoreductive hepatic 
surgery has been reported to be approximately 
90%160），161），193），196），197）. Furthermore, Chung et al. have 
reported that the rate of remission of hormonal 
symptoms by cytoreduction removing at least 70-90% 
of the tumor burden, followed by administration of an 
adjuvant long-acting somatostatin analog, was 87%198）. 
Although Osborne et al. have indicated improvement 
of prognosis using cytoreductive hepatic surgery197）, 
there is insufficient evidence for the efficacy of 
cytoreductive hepatic surgery for patients other than 
those who have hormonal symptoms resistant to 
medical therapy. 
Surgical treatment for other sites of metastasis
There are few reports about surgical treatment for 
lung metastasis from NETs199）. Although it is difficult 
to suggest any definitive therapeutic approach, 
patients who have no metastasis other than in the 
lung, metastatic tumors with low proliferative rates, 
and sufficient pulmonary function to tolerate lung 
resection may be suitable candidates for resection of 
lung metastasis.
In relation to peritoneal metastasis, 82-97% of 
patients with peritoneal metastasis from NETs have 
liver metastasis, and liver metastasis is a prognostic 
factor for patients with peritoneal metastasis200），201）. In 
addition, extrahepatic metastasis such as peritoneal 
metastasis is a poor prognostic factor for patients 
with liver metastasis165），167）. Therefore, therapy 
for liver metastasis and peritoneal metastasis 
may be important for improving prognosis. In 
terms of therapy for peritoneal metastasis, Ellias 
et al. reported that the 5- and 10-year survival 
rates for patients who had liver and peritoneal 
metastasis from well-differentiated NETs and who 
underwent resection of these metastases along with 
intraperitoneal chemotherapy using mitomycin C 
and 5-fluorouracil were 71% and 31%, respectively; 
the outcome was unaffected by whether peritoneal 
metastasis was present or not157）. Resection of 
peritoneal metastasis may be indicated if it can be 
done safely, as a part of combined therapy.
Local recurrence may also be an indication for 
surgery if the tumor is resectable. Schurr et al. 
reported that aggressive resection for recurrences 
including local recurrence had a tendency to improve 
overall and disease-free survival202）. 
Postoperative surveillance for P-NETs
Postoperative follow-up for at least 10 years is 
needed because long-term recurrence can occur 
after surgery203）. Laboratory investigations and 
ultrasonography are required every 3 months 
during the first 2 years and CT is required every 6 
months. Thereafter, laboratory investigations and 
ultrasonography are recommended every 6 months 
and CT is recommended yearly29）.
Multiple primary cancers such as breast, prostate, 
bladder, and ovarian cancer occurred in 13% of 
P-NETs and approximately 20% of gastrinoma 
and nonfunctioning P-NETs31）. Therefore, careful 
observation and follow-up are required due to the 
possibility of multiple primary cancers.
Blood levels of gastrin, insulin, glucagon, and 
others can be used as indicators of recurrence of 
functioning P-NETs. Neuron-specific enolase is 
used as a tumor marker for poorly differentiated 
NETs204）. Somatostatin receptor scintigraphy205），206）and 
serum chromogranin A are used in postoperative 
follow-up207）. Serum chromogranin A is useful for 
determining recurrence and the effect of treatment, 
regardless of whether P-NET is functioning or 
nonfunctioning208）－210）. Single-photon emission CT 
imaging in somatostatin receptor scintigraphy gave 
a sensitivity of 92.3% for liver metastases. This value 
is superior to those for planar imaging（58.5%）and 
CT, MRI, and ultrasonography（80%）211）. 
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